ARS Pharmaceuticals

SPRY

Market cap $1.05B

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ: AQST).

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market  neffy  in China under the trade name 优敏速 ® , expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the National Medical Products Administration (NMPA) in China has granted approval for  neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more. In China, the trade name is 优敏速 ® meaning “Excellent Allergy (treatment) Fast”.

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York.

ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President, CEO & Director Eric Karas - Chief Commercial Officer Kathleen Scott - Chief Financial Officer Conference Call Participants Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Kevin Holder - ROTH Capital Partners, LLC, Research Division Presentation Operator Good morning and welcome to ARS Pharmaceuticals Conference Call.

ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics and upcoming alternatives, but patent litigation could delay generic Neffy entry until 2039. Neffy's needle-free, lower-cost profile is driving adoption, with growing prescriber base and international launches, but long-term profitability remains uncertain.

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago.

$32.5 million in revenue, including $31.3 million in  neffy U.S. net product revenue in third quarter of 2025

Offers no-hassle, free  virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may already have an auto-injector, but are looking for a smaller, easier to administer option SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced the launch of “Get  neffy on Us,” a new integrated commercial program to help patients access their needle-free epinephrine medicine, neffy . Get neffy on Us was created to eliminate the time burden of an in-person office visit by offering a free visit with a virtual provider who can prescribe neffy.

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of  neffy ® (epinephrine nasal spray) Oral presentation to report results from real world data on the effectiveness of epinephrine nasal spray in clinical practice Case reports to detail real-world data and effective use of neffy in patients who experience anaphylaxis during oral food challenges or allergy immunotherapy SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that one late-breaking oral and six poster presentations will be featured at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place November 6-10, 2025, in Orlando, FL. The presentations highlight real-world experience associated with intranasal epinephrine.

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m.